Quick Answer
WEST PHARMACEUTICAL SERVICES INC reported Revenue From Contract With Customer Excluding Assessed Tax of $3.07 billion for the year ending 2025.
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +6.3% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from WEST PHARMACEUTICAL SERVICES INC's annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $443.50 million | Q2 2019: $469.70 million | Q3 2019: $456.10 million | Q4 2019: $470.60 million | Q1 2020: $491.50 million | Q2 2020: $527.20 million | Q3 2020: $548.00 million | Q4 2020: $580.20 million | Q1 2021: $670.70 million | Q2 2021: $723.60 million | Q3 2021: $706.50 million | Q1 2022: $720.00 million | Q2 2022: $771.30 million | Q3 2022: $686.90 million | Q1 2023: $716.60 million | Q2 2023: $753.80 million | Q3 2023: $747.40 million | Q1 2024: $695.40 million | Q2 2024: $702.10 million | Q3 2024: $746.90 million | Q1 2025: $698.00 million | Q2 2025: $766.50 million | Q3 2025: $804.60 million.
- Over the full 8 years of available data (2018 to 2025), WEST PHARMACEUTICAL SERVICES INC's Revenue From Contract With Customer Excluding Assessed Tax has grown by 79.0%.
- Historical annual values: Fiscal year 2025: $3.07 billion | Fiscal year 2024: $2.89 billion | Fiscal year 2023: $2.95 billion | Fiscal year 2022: $2.89 billion | Fiscal year 2021: $2.83 billion | Fiscal year 2020: $2.15 billion | Fiscal year 2019: $1.84 billion | Fiscal year 2018: $1.72 billion.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: